ClinicalTrials.gg
RecruitingNCT05492136LIVERaTIONUpdated Jul 21, 2026

Unravelling the Impact of Radiofrecuency in Liver Surgery: the Key to Decrease Local Recurrence?

An interventional study of Additional margin coagulation in Liver Cancer and Cancer, Treatment-Related, sponsored by Hospital del Mar. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Hospital del Mar · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Liver Neoplasms with a site in Spain — 7 open to participants now, 17 under way, 4 of them phase 3. Liver Neoplasms · Spain.

Planned enrollment
5th of 39
720 · median 201
Started
2023
with 3 others
No phase
6 of 48
2 open now
Primary completion
2028-05
later than 14 of 16 live
Registered
42nd of 48
by date

Among the 48 studies in Liver Neoplasms with a site in Spain, this one is the 5th largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2023, is one of 6 with no phase, reaches primary completion later than 14 of the 16 other live ones, and was the 42nd registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

7 of the 48 studies in Liver Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Liver Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

Radiofrequency devices have been increasingly employed in liver surgery in order to achieve proper hemostasis and this use has become more evident with the implementation of minimal invasive surgery. Due to its well-known efficacy for tumor ablation (i.e. hepatocarcinoma) it use has been extended in some cases to ablate the liver surface after resection in questionable resection. Till date, despite the majority of surgeons apply an additional coagulation in doubtful margins, there is not an evidence that this maneuver really decreases the local recurrence or increases the overall survival. On the contrary, some studies have suggested that non-anatomical resections in order to spare liver parenchyma could lead to major zones of liver ischemia in the remnant liver and thus favoring recurrence. However, major liver ischemia (defined as grade 2 o more) is unlikely to be provoked by 1 cm-depth additional coagulation of the margin.

The investigators previously published in a retrospective study the concept of additional margin coagulation within liver resections and narrow margins and demonstrated that the study group had significantly less local recurrence compared to the controls. Therefore, in the present study the aim is to continue this evaluation through a multicenter randomized clinical trial.

03

Conditions studied

  • Liver Cancer
  • Cancer, Treatment-Related
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written granted prior to the initiation of the surgical procedure, given with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.
  2. 18 year of age or older.
  3. WHO performance scale 0-2
  4. Consecutive patients (both sexes equally distributed) suffering from CRLM confirmed either by abdominal CT, abdominal MRI or/and by histologic-cytological evaluation or patients suffering from HCC.
  5. Any previous chemotherapy regime is permitted.
  6. 1 to 3.

Exclusion criteria

Exclusion criteria:

  1. Previous or concurrent cancer that is distinct from one primary tumor of which the Liver comes from EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis \& T1).
  2. Any cancer curatively treated > 3 years prior to enrollment is permitted.
  3. ASA 4.
  4. Non-resectable extrahepatic metastases.
  5. Liver metastasis from other origin apart from colorectal.
  6. Bening primary tumor of the liver.
  7. Pregnant woman.
  8. Participation in another clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
720 participants (estimated)

Study arms

  • No intervention
    Arm 1: Control

    In this arm it will be permitted one/several conventional methods according to surgeon preference: * Conventional crusch-clamp or finger fracture technique * Ultrasonic dissector (CUSA, SONOK..) or Ultrasonic mediated devices * Water jet dissector * Argon beam coagulator

  • Experimental
    Arm 2: study arm

    In this arm it will be permitted to use the radiofrequency devices which have demonstrated evidence in the literature in terms of reducing local recurrence alone or in combination with any conventional method described previously in Arm. (Coolingbis device by VecMedical as well as Aquamantys (Medtronic) These devices and their operating procedure have been described in detail elsewhere Briefly, it consists of a handheld instrument that might be employed not only for margin coagulation but also as hemostatic instrument. After performing the hepatectomy the bladeless part of the device should be applied onto the surgical margin following the protocol 3-4 s/cm2 of liver transection surface at maximum power output.in order to perform an additional margin coagulation

    Procedure: Additional margin coagulation

Interventions

  • ProcedureAdditional margin coagulation

    After performing the hepatectomy the selected device should be applied onto the surgical margin following the protocol 3-4 s/cm2 of liver transection surface at maximum power output in order to perform an additional margin coagulation

06

What researchers measure

Primary outcomes

  1. Local recurrence

    Local recurrence (LR): defined as any growing or enhancing tumour in the margin of hepatic resection specifically reviewed to this aim in a later follow-up imaging

    Time frame: 5 years follow-up

Secondary outcomes

  1. overall survival (OS)

    defined as time from surgery until death or the end of the study, patients who discontinue from the study without disease will be censored at the time of their last tumour evaluation prior to death or discontinuation.

    Time frame: From the surgery to death or lost of follow-up whichever came first, assessed up to 24 months

  2. Disease free survival (DFS)

    Disease free survival (DFS), calculated as the time from surgery until disease progression, patients who have not progressed at the time the SVR analysis is performed will be censored at the time of their last tumour evaluation

    Time frame: 2 years of follow-up

  3. Cancer specific survival (CSS)

    Cancer-specific survival (CSS), measured from the date of surgery to the date of death from colorectal cancer/HCC or last follow-up.

    Time frame: From the surgery to recurrence/last follow-up whichever came first, assessed up to 24 months

  4. Postoperative complications

    Graded by Clavien-Dindo clasification and CCI

    Time frame: 90 days after surgery

  5. Hepatic recurrence

    Tumoral recurrence within the liver

    Time frame: From the surgery to hepatic recurrence or lost of follow-up whichever came first, assessed up to 24 months

07

Study locations

1 of 1 sites recruiting
  • Hospital del Mar Research Institute
    Barcelona, Spain
    Recruiting
    • Carlos Fuste, MD PhD · Contactcfuste@imim.es
    • Fernando Burdío, MD PhD · Sub investigator
    • Benedetto Ielpo, MD PhD · Sub investigator
08

References and documents

Publications

  • Luque Villalobos E, Ielpo B, Aldrighetti L, Anselmo A, Beghdadi N, Berardi G, Briceno F, Ciria R, Dorcaratto D, Durczynski A, Ettorre GM, Delvecchio A, Ferri V, Grat M, Garces-Albir M, Grochola LF, Hogendorf P, Izzo F, Kobryn K, Kontis E, Korkolis D, Krol R, Lesurtel M, Lopez-Ben S, Christogiannis C, Koutsiouroumpa O, Mavridis D, Memeo R, Murawa D, Machairas N, Mora-Oliver I, Munoz-Forner E, Orrego C, Dantas C, Fuste C, Garcia Picazo A, Pessaux P, Pilat T, Pittau G, Radosevic A, Ratti F, Sotiropoulos G, Toutouzas K, Trotovsek B, Wystrychowski W, Zacharoulis D, Vicente E, Burdio F, Sanchez Velazquez P. LIVERATION trial: a multicentre European randomised study on radiofrequency margin coagulation and its impact on oncological outcomes after liver surgery - study protocol. BMJ Open. 2025 Nov 24;15(11):e100518. doi: 10.1136/bmjopen-2025-100518. PubMed 41290310 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for May 2028, 54 months after the start.

Of 149 non-industry interventional studies with no phase under Liver Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 73. This study's planned 54 months is above that.

Counting every sponsor, half of 168 studies reached it within 39 months; a quarter within 18 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2022
First posted
Aug 8, 2022
StartActual
Nov 1, 2023
Primary completionEst.
May 31, 2028
CompletionEst.
Jun 30, 2028
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05492136
Lead sponsor
Hospital del Mar
Responsible party
Patricia Sanchez Velazquez (Principal Investigator, Hospital del Mar) — Principal investigator
First posted
Aug 8, 2022
Start date
Nov 1, 2023
Primary completion
May 31, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jul 21, 2026

Study contacts

Carlos fuste, MD PhD
Contact
cfuste@imim.es
0034 932483207
Patricia Sánchez Velazquez, MD PhD FEBS
principal investigator · Hospital del Mar

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion